Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial (Q24807379)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial	scientific article

Statements

scholarly article

0 references

Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial (English)

0 references

0 references

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

10

object named as

Oriana Nanni

0 references

Alessandra Ravaioli

object named as

Alessandra Ravaioli

2

0 references

Roberto Labianca

object named as

Roberto Labianca

5

0 references

author name string

Michele Guida

1

0 references

Vanna Chiarion Sileni

3

0 references

Antonella Romanini

4

0 references

Antonio Freschi

6

0 references

Salvatore Brugnara

7

0 references

Addolorata Casamassima

8

0 references

Vito Lorusso

9

0 references

Ruggero Ridolfi

11

0 references

publication date

22 December 2003

0 references

Journal of Translational Medicine

0 references

1

0 references

1

0 references

13

0 references

Cancer statistics, 2001

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

7 April 2017

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Pretreatment serum markers and lymphocyte response to interleukin-2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Prognostic factors for survival of patients treated systemically for disseminated melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

The relationship between weight loss and interleukin 6 in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Prognostic factors in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Decreased interleukin-2 production in patients with gastrointestinal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 September 2017

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

30 May 2018

Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

30 May 2018

Generation of monoclonal antibodies against HILDA/LIF and their use in the quantitative assay of the cytokine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

30 May 2018

Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

30 May 2018

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

30 May 2018

Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

30 May 2018

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Cancer statistics, 1996.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Prognostic factors for survival in patients with inoperable lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=320500

28 November 2018

Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombosis and cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies in prognostic factors relating to chemotherapy for advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The acute phase response

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14690541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-1-13

0 references

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1479-5876-1-13

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24807379&oldid=2176992384"